Clinical Trial Update: Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Phase 2]

View source ↗

Summary

Phase II study evaluating decitabine in chronic myeloid leukemia in blast phase patients refractory to imatinib; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Decitabine (Dacogen) (decitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED